Jazz Pharmaceuticals plc — Director's Dealing 2018

Nov 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-11-15

Reporting Person: Mulligan Seamus (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-15	Ordinary Shares	P	300	$141.8633	Acquired	1051168	Direct
2018-11-15	Ordinary Shares	P	1200	$143.2242	Acquired	1052368	Direct
2018-11-15	Ordinary Shares	P	26363	$144.2431	Acquired	1078731	Direct
2018-11-15	Ordinary Shares	P	22137	$145.0464	Acquired	1100868	Direct

Footnotes

F1: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $141.52 to $142.04. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F2: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $142.67 to $143.60. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F3: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $143.69 to $144.67. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.

F4: Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $144.69 to $145.56. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.